|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Johns Hopkins University |
|---|---|
| Information provided by: | Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT00127114 |
Purpose
The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia.
| Condition | Intervention | Phase |
|---|---|---|
|
Dementia |
Drug: amantadine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) |
| Estimated Enrollment: | 52 |
| Study Start Date: | September 2005 |
Behavioral disturbances are a major cause of morbidity in frontotemporal dementia (FTD), yet little is known about the effectiveness of medications to treat these disturbances. Preliminary data suggests that the dopaminergic agent amantadine may reduce these disturbances. This 6-week, prospective, randomized, placebo-controlled trial will compare amantadine to placebo to assess its effectiveness in reducing behavioral symptoms.
Eligibility| Ages Eligible for Study: | 40 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Maryland | |
| Johns Hopkins University School of Medicine, Outpatient General Clinical Research Center | |
| Baltimore, Maryland, United States, 21287 | |
| Principal Investigator: | David M Blass, M.D. | Johns Hopkins University |
More Information
| Responsible Party: | Dr. David Mark Blass, Johns Hopkins University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00127114 History of Changes |
| Other Study ID Numbers: | 04033101 |
| Study First Received: | August 3, 2005 |
| Last Updated: | March 16, 2009 |
| Health Authority: | United States: Institutional Review Board |
|
Behavioral disturbance Frontotemporal dementia Dementia Amantadine Behavioral disturbance due to frontotemporal dementia |
|
Dementia Frontotemporal Dementia Aphasia, Primary Progressive Pick Disease of the Brain Brain Diseases Central Nervous System Diseases Nervous System Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Frontotemporal Lobar Degeneration TDP-43 Proteinopathies Neurodegenerative Diseases Proteostasis Deficiencies Metabolic Diseases Aphasia |
Speech Disorders Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Amantadine Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Antiviral Agents Anti-Infective Agents Dopamine Agents |